Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Deszk – page 18

383 clinical trials in Deszk, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Deszk at a glance
383
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

383 trials in Deszk

Open in trial search

Colitis ulcerative

Not recruiting

Study on the Effects of Guselkumab and Golimumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years
  • Substances:Golimumab
  • Sponsor:Janssen - Cilag International

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:Astrazeneca AB

Arteriosclerosis

Not recruiting

Study of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Novartis Pharma AG

Systemic scleroderma

Not recruiting

Study of anifrolumab effectiveness compared to placebo in adults aged 18-70 with systemic sclerosis

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:Astrazeneca AB

Ischaemic stroke+2

Not recruiting

Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Asundexian
  • Sponsor:Bayer AG

Study on Long-Term Safety and Efficacy of Deucravacitinib for Patients with Systemic Lupus Erythematosus

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol Myers Squibb International Corporation

Breast cancer

Not recruiting

Study of Pembrolizumab and Chemotherapy for Patients with HR+/HER2- Advanced Breast Cancer

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Psoriatic arthropathy

Not recruiting

Study on Deucravacitinib and Apremilast for Patients with Active Psoriatic Arthritis New to Biologic Treatments or Previously on TNFα Inhibitors

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 for Treating Moderate to Severe Plaque Psoriasis in Adults

Investigational
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Icotrokinra
  • Sponsor:Janssen - Cilag International

Endometriosis

Not recruiting

Study on the Effectiveness and Safety of OG-6219 and Naproxen Sodium for Women Aged 18-49 with Moderate to Severe Endometriosis Pain

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years
  • Substances:FOR-6219
  • Sponsor:Organon LLC

Bladder cancer

Not recruiting

Study of Pembrolizumab and BCG for Patients with High-Risk Non-Muscle Invasive Bladder Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Effectiveness and Safety of Deucravacitinib for Patients with Active Systemic Lupus Erythematosus (SLE)

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Deszk

What the registry says about research in the country

01 Lung Cancer Research

Innovative clinical trials focusing on non-small cell lung cancer (NSCLC) treatments, particularly targeting advanced and unresectable cases.

  • Advanced Non-Squamous NSCLC with HER2 Mutations
  • Stage III Unresectable NSCLC
  • Combination Therapy Approaches

Studies evaluating novel therapeutic agents including zongertinib and combination treatments with durvalumab plus domvanalimab to improve patient outcomes.

02 Targeted Therapies

Research examining personalized treatment approaches for patients with specific genetic markers and protein expressions.

  • HER2 Mutation-Targeted Treatments
  • PD-L1 Expression Analysis
  • Immunotherapy Combinations

Investigations comparing new targeted therapies against standard-of-care treatments for better progression-free survival.

03 Treatment Innovation

Advancement in therapeutic strategies for locally advanced lung cancer patients.

  • Chemoradiation Therapy
  • Novel Drug Combinations
  • Biomarker-Driven Research

Focus on developing improved treatment options for patients with unresectable stage III NSCLC following concurrent chemoradiation.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.